Bedfont® acquires US-based company coVita™, marking the next chapter in its global growth

MAIDSTONE, U.K. - EntSun -- Bedfont® Scientific Limited, a leading MedTech company with 50 years of experience designing and manufacturing medical breath analysis devices, has taken the next step in its global expansion by acquiring coVita™ LLC. The acquisition positions Bedfont® to further penetrate the US market with its innovative breath analysis devices, including the NObreath® Fractional exhaled Nitric Oxide (FeNO) device.

coVita™, a US medical device company based in The Woodlands, Texas, has served as Bedfont's US distributor for more than 16 years, helping expand its breath analysis technologies across the US. With its extensive knowledge, coVita™ has provided valuable insight into the US healthcare market, helping Bedfont® understand local needs, navigate market opportunities, and strengthen its presence across the region.

More on EntSun News

• Colony Ridge Fall Festival: Two Days of Free Family Fun in Cleveland, Texas
• Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
• Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
• Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
• New Horror Film from BayView Entertainment Dares Viewers to 'Invite the Devil to Come and Play'

"This acquisition represents an exciting new chapter for Bedfont® and builds on the strong relationship we have developed with coVita™ over many years. At the heart of everything we do is our commitment to improving healthcare through accessible, simple and non-invasive breath analysis." Says Jason Smith, CEO of Bedfont®.

Jason Aversano, Co-founder and CEO of coVita™ says, "Becoming part of Bedfont® is a natural next step in that journey. Our leadership and team will remain the same, so our customers can expect the same people and the same dedicated local support they know and trust. What changes is the pace. With Bedfont's full resources behind us, we'll be able to grow faster, reach more clinicians and support more research across the US and world."

After Keensight's majority stake in Bedfont® in 2025, this marks another new chapter in Bedfont's history. The acquisition allows Bedfont® to continue building on coVita's success, especially in the US FeNO market. As Bedfont® puts more focus on clinical research, a US base provides access to a major clinical research market and enables localised distribution, training, and technical support.

More on EntSun News

• Laurent Gabay and Fashion Sourcing: Setting the Standard for High-End Ladies' Purses
• How Laurent Gabay and Fashion Sourcing Are Transforming High-End Clothing Manufacturing
• Laurent Gabay on the Importance of Fashion Sourcing: Where to Find the Best Products Worldwide
• Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
• Vegan Kingz Expands Direct-Import Wholesale Lineup to Help Commercial Kitchens Cut Ingredient Costs

The announcement coincides with coVita's attendance at this year's CHEST annual meeting. The event brings together healthcare professionals interested in pulmonary, critical care, and sleep medicine. Taking place between the 18^th and 21^st of October in Phoenix, Arizona, coVita™ will be at booth 1263, showcasing the innovative NObreath® FeNO device.

Building on its long-standing partnership with coVita™, Bedfont® combines its breath analysis expertise with established US market knowledge and infrastructure, strengthening NObreath's proposition for multicentre clinical trials and improving access to objective testing to aid asthma diagnosis and management. To learn more about Bedfont®, visit the website here (https://www.bedfont.com/).